Garsorasib
A novel combination therapy of garsorasib and cetuximab for KRAS G12C mutated colorectal cancer patients
Anika Sharma
D‐1553 is a small-molecule inhibitor designed to selectively target KRAS G12C and is currently undergoing Phase II clinical trials. It ...
Results from Garsorasib Expand the Class of KRASG12C Inhibitors in NSCLC
SG Tylor
Early findings from the use of garsorasib (D-1553), an oral KRASG12C inhibitor, in patients with advanced non–small cell lung cancer ...
